+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Conjugate Vaccine Market by Product Type, Age Group, Distribution Channel, Technology, End User - Global Forecast to 2030- Product Image
Conjugate Vaccine Market by Product Type, Age Group, Distribution Channel, Technology, End User - Global Forecast to 2030- Product Image
Sale

Conjugate Vaccine Market by Product Type, Age Group, Distribution Channel, Technology, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896495
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Conjugate Vaccine Market grew from USD 43.92 billion in 2024 to USD 48.92 billion in 2025. It is expected to continue growing at a CAGR of 10.85%, reaching USD 81.51 billion by 2030.

Shaping the Future of Conjugate Vaccines

Conjugate vaccines have redefined the fight against bacterial pathogens by harnessing advanced immunological principles that link polysaccharide antigens to protein carriers. This innovation has enhanced the immune response against major disease burdens such as Haemophilus influenzae type b, pneumococcus, and meningococcus across diverse age cohorts. As preventive healthcare becomes increasingly central to public health strategies, conjugate vaccines stand at the forefront of immunization programs, driving significant reductions in morbidity and mortality globally.

In this executive summary, we deliver a comprehensive assessment of the conjugate vaccine market, examining pivotal technological advancements, regulatory dynamics, and shifting distribution models. Our analysis weaves together the impact of emerging policies, the ripple effects of new tariffs, granular segmentation insights, and regional performance factors. By drawing on validated data and expert stakeholder perspectives, this report equips decision-makers with actionable intelligence to navigate a competitive landscape and capitalize on evolving opportunities.

Revolutionary Forces Redefining Conjugate Vaccination

In recent years, technology breakthroughs in carrier proteins and adjuvant systems have sparked a renaissance in conjugate vaccine development, elevating efficacy benchmarks and streamlining production. Novel platforms such as CRM197 and refined toxoid carriers have delivered more robust immunogenicity across challenging serotypes. At the same time, regulatory bodies have accelerated pathways for priority vaccine candidates, expediting approvals while maintaining rigorous safety and quality standards.

Simultaneously, strategic alliances between pharmaceutical innovators, contract manufacturing organizations, and global health entities have fostered integrated development models. These collaborative frameworks have optimized resource utilization, from antigen discovery through fill-and-finish stages. Coupled with the rise of digital supply chain management and real-time monitoring tools, these transformative shifts are redefining how conjugate vaccines reach diverse populations and scale to meet surging demand.

Navigating the Toll of 2025 US Tariffs on Vaccine Dynamics

The introduction of targeted United States tariffs in 2025 on key vaccine inputs and intermediate components has reshaped supply chain economics and pricing strategies. Tariffs on conjugate vaccine carriers, adjuvant materials, and primary packaging have elevated production costs, prompting manufacturers to reassess procurement protocols. In response, many producers have pursued dual-sourcing strategies or relocated certain manufacturing processes to tariff-exempt jurisdictions. These adjustments have helped contain cost escalations yet introduced new complexities in quality assurance and regulatory compliance.

Healthcare payers and government purchasers have felt these cost pressures acutely, leading to more stringent tender evaluations and requests for price concessions. Some vendors have absorbed a portion of the tariff impact to maintain competitive listings, while others have introduced tiered pricing models to protect profitability. Looking ahead, sustained dialogue between industry stakeholders and trade policymakers will be essential to harmonize tariff frameworks with public health imperatives. Navigating this evolving landscape requires agility in sourcing, robust risk mitigation plans, and proactive engagement with procurement authorities.

Dissecting Market Segments for Strategic Clarity

The conjugate vaccine market can be meticulously deconstructed by evaluating product type, age group, distribution channels, technology, and end user, each offering unique strategic insights. The Hib conjugate vaccine portfolio remains critical in infant immunization schedules, yet the pneumococcal conjugate segment commands increasing attention due to its broad serotype coverage and elevated public health prioritization. Meningococcal conjugate vaccines continue to benefit from targeted adolescent and young adult immunization campaigns designed to curb outbreak risks in communal settings.

Age group analysis reveals nuanced growth pockets. Adolescents and children aged two to twelve are key beneficiaries of catch-up and booster initiatives, while adult cohorts between nineteen and sixty years are gravitating toward combination immunization strategies. Infants under two years represent a foundational market, supported by established pediatric programs. Distribution channels vary markedly in reach and adoption patterns. Clinics and hospitals underpin traditional administration, whereas online platforms and pharmacies are emerging as convenient access points. From a technology perspective, carriers such as CRM197 dominate, though alternative toxoid formulations bolster the competitive landscape. Finally, private clinics and hospitals drive premium product uptake, while public clinics and hospitals ensure broad-based coverage through government tenders.

Regional Dynamics Driving Global Vaccine Adoption

Regional performance across the Americas, Europe, Middle East and Africa, and Asia-Pacific reveals distinct drivers and challenges. In the Americas, well-capitalized public health systems and broad insurance coverage underpin high vaccination uptake, particularly for adult booster programs. Procurement cycles remain competitive, with volume tenders shaping supplier strategies.

Across Europe, Middle East and Africa, regulatory harmonization efforts under regional blocs facilitate cross-border market entry, though economic disparities influence pricing negotiations. Immunization initiatives for infants and adolescents receive strong backing from global health partnerships. In Asia-Pacific, expanding middle-income populations and strengthening healthcare infrastructures propel demand within private clinics and hospitals, while domestic manufacturers are rapidly scaling production to serve both regional and export markets. Each region’s unique policy environment and healthcare landscape inform tailored market approaches.

Leading Organizations Steering the Conjugate Vaccine Market

Several leading organizations anchor innovation and production in the conjugate vaccine landscape. Industry stalwarts have invested heavily in next-generation carrier molecules and adjuvant enhancements to extend serotype coverage and improve durability of immune response. Strategic mergers and acquisitions have consolidated manufacturing capacities, enabling economies of scale in global fill-finish operations. Beyond established players, emerging biotechnology firms are advancing niche conjugate constructs that address serogroup-specific challenges or develop combination formulations to streamline immunization schedules.

Collaborative research partnerships with academic institutions and contract research organizations have accelerated translational development of pipeline candidates. Simultaneously, alliances with logistics specialists and digital health providers have optimized cold-chain integrity and immunization tracking. This confluence of scientific, operational, and strategic initiatives by key market participants continues to redefine competitive benchmarks and expand the overall reach of conjugate vaccination programs.

Strategic Imperatives for Industry Trailblazers

Vaccine developers and distributors should prioritize investment in scalable manufacturing technologies that support flexible batch sizes and rapid formulation adjustments. Strengthening the resilience of supply chains through diversification and nearshoring can mitigate tariff and geopolitical risks. Tailoring product offerings to demographic nuances by advancing targeted formulations for infants, children, adults, and the elderly will enhance market penetration and patient adherence.

Engagement with digital distribution channels, including e-pharmacies and telehealth platforms, can accelerate access and caregiver convenience. Furthermore, deepening collaborations with public health authorities to co-design immunization campaigns will reinforce demand forecasts and secure long-term procurement agreements. By adopting adaptive pricing strategies that balance profitability with affordability, industry leaders can sustain growth in both private and public sector markets.

Rigorous Methodology Underpinning Our Analysis

Our research methodology integrates a balanced blend of primary and secondary data gathering to ensure comprehensive, validated insights. Primary research encompassed structured interviews with senior executives across vaccine developers, contract manufacturers, distributors, and regulatory agencies, supplemented by expert panel discussions to challenge emerging hypotheses. These direct engagements provided qualitative depth and real-time perspectives on market dynamics.

Secondary research involved systematic analysis of public regulatory filings, peer-reviewed journals, market data repositories, and trade association reports. We applied triangulation techniques to cross-verify quantitative and qualitative inputs, ensuring consistency and reliability. A rigorous data validation process, underpinned by quality assurance protocols, confirms the robustness of our segmentation framework and regional performance assessments. This methodological rigor underlies every insight presented in this report.

Consolidating Insights for Future Vaccine Strategies

The conjugate vaccine landscape stands at a crossroads where scientific innovation, policy evolution, and market forces converge. Advances in carrier protein technologies and adjuvant systems are expanding protective coverage, while collaborative development models are accelerating availability across geographies. At the same time, shifting trade policies and tariff structures are reshaping supply chain economics, compelling stakeholders to adopt more agile and diversified sourcing strategies.

Granular segmentation analysis has highlighted high-growth pockets among specific age cohorts and distribution channels, informing targeted market entry and expansion plans. Meanwhile, region-specific dynamics-from robust procurement in the Americas to manufacturing surges in Asia-Pacific-underscore the need for locally tailored approaches. As industry leaders invest in next-generation platforms, the strategic imperative is clear: combine scientific rigor with operational flexibility and stakeholder collaboration to sustain momentum in the global conjugate vaccine market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Hib Conjugate Vaccine
    • Meningococcal Conjugate Vaccine
    • Pneumococcal Conjugate Vaccine
  • Age Group
    • Adolescents
    • Adults
      • 19 To 40 Years
      • 41 To 60 Years
    • Children
      • 2 To 5 Years
      • 6 To 12 Years
    • Elderly
    • Infants
      • 0 To 12 Months
      • 13 To 24 Months
  • Distribution Channel
    • Clinics
    • Hospitals
    • Online
    • Pharmacies
  • Technology
    • Crm197
    • Dt
    • Tt
  • End User
    • Private Clinics
    • Private Hospitals
    • Public Clinics
    • Public Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech International Ltd.
  • Panacea Biotec Ltd.
  • SK bioscience Co., Ltd.
  • Bavarian Nordic A/S
  • Biological E. Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Conjugate Vaccine Market, by Product Type
8.1. Introduction
8.2. Hib Conjugate Vaccine
8.3. Meningococcal Conjugate Vaccine
8.4. Pneumococcal Conjugate Vaccine
9. Conjugate Vaccine Market, by Age Group
9.1. Introduction
9.2. Adolescents
9.3. Adults
9.3.1. 19 to 40 Years
9.3.2. 41 to 60 Years
9.4. Children
9.4.1. 2 to 5 Years
9.4.2. 6 to 12 Years
9.5. Elderly
9.6. Infants
9.6.1. 0 to 12 Months
9.6.2. 13 to 24 Months
10. Conjugate Vaccine Market, by Distribution Channel
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Online
10.5. Pharmacies
11. Conjugate Vaccine Market, by Technology
11.1. Introduction
11.2. Crm197
11.3. Dt
11.4. Tt
12. Conjugate Vaccine Market, by End User
12.1. Introduction
12.2. Private Clinics
12.3. Private Hospitals
12.4. Public Clinics
12.5. Public Hospitals
13. Americas Conjugate Vaccine Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Conjugate Vaccine Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Conjugate Vaccine Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Sanofi S.A.
16.3.4. Merck & Co., Inc.
16.3.5. Serum Institute of India Pvt. Ltd.
16.3.6. Bharat Biotech International Ltd.
16.3.7. Panacea Biotec Ltd.
16.3.8. SK bioscience Co., Ltd.
16.3.9. Bavarian Nordic a/S
16.3.10. Biological E. Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CONJUGATE VACCINE MARKET MULTI-CURRENCY
FIGURE 2. CONJUGATE VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. CONJUGATE VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CONJUGATE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY HIB CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY 19 TO 40 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY 41 TO 60 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY 2 TO 5 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY 6 TO 12 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY 0 TO 12 MONTHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY 13 TO 24 MONTHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CRM197, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PUBLIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. CANADA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 59. CANADA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 60. CANADA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 61. CANADA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 62. CANADA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. CANADA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. MEXICO CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. MEXICO CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. GERMANY CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. GERMANY CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. GERMANY CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 109. GERMANY CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 110. GERMANY CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 111. GERMANY CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. GERMANY CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. GERMANY CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. FRANCE CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. FRANCE CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 117. FRANCE CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. ITALY CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. ITALY CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 133. ITALY CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 134. ITALY CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 135. ITALY CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ITALY CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. ITALY CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. SPAIN CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. SPAIN CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. SPAIN CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 141. SPAIN CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 142. SPAIN CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 143. SPAIN CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SPAIN CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. SPAIN CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. DENMARK CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. DENMARK CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. DENMARK CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 174. DENMARK CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. DENMARK CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. DENMARK CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. QATAR CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. QATAR CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 189. QATAR CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 190. QATAR CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 191. QATAR CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 193. QATAR CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. FINLAND CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. FINLAND CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. FINLAND CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 197. FINLAND CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 198. FINLAND CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 199. FINLAND CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FINLAND CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. FINLAND CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. EGYPT CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. EGYPT CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 220. EGYPT CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 221. EGYPT CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 222. EGYPT CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 223. EGYPT CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. EGYPT CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. EGYPT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. TURKEY CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. TURKEY CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 230. TURKEY CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TURKEY CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. TURKEY CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. NORWAY CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. NORWAY CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. NORWAY CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 245. NORWAY CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 246. NORWAY CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 247. NORWAY CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NORWAY CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. NORWAY CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. POLAND CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. POLAND CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. POLAND CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 253. POLAND CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 254. POLAND CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 255. POLAND CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. POLAND CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. POLAND CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 275. CHINA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. CHINA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. CHINA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 278. CHINA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 279. CHINA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 280. CHINA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. CHINA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. CHINA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. INDIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. INDIA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. INDIA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 286. INDIA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 287. INDIA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 288. INDIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. INDIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 290. INDIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. JAPAN CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. JAPAN CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. JAPAN CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 294. JAPAN CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 295. JAPAN CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 296. JAPAN CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. JAPAN CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. JAPAN CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. THAILAND CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 324. THAILAND CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 325. THAILAND CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 326. THAILAND CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 327. THAILAND CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 328. THAILAND CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. THAILAND CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 330. THAILAND CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 338. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 346. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 349. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 350. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 351. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 352. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 353. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 354. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 356. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 357. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 358. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 359. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 360. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 361. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD

Companies Mentioned

The companies profiled in this Conjugate Vaccine market report include:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech International Ltd.
  • Panacea Biotec Ltd.
  • SK bioscience Co., Ltd.
  • Bavarian Nordic A/S
  • Biological E. Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 48.92 Billion
Forecasted Market Value ( USD ) by 2030 $ 81.51 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product (Monovalent, Multivalent), By Brand (Prevnar, CAPVAXIVE), By Disease, By Pathogen, By Patient, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product (Monovalent, Multivalent), By Brand (Prevnar, CAPVAXIVE), By Disease, By Pathogen, By Patient, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Conjugate Vaccines - Global Strategic Business Report - Product Image

Conjugate Vaccines - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Conjugate Vaccine Market Report 2025 - Product Image

Conjugate Vaccine Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 184 Pages
  • Global
From
Conjugate Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Conjugate Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From

About the Conjugate Vaccine Market

The Conjugate Vaccine market is a subset of the Vaccines market, which is composed of products designed to prevent and treat infectious diseases. Conjugate Vaccines are a type of vaccine that combines a polysaccharide antigen with a protein carrier, which helps the body to recognize the antigen and mount an immune response. These vaccines are used to protect against a variety of bacterial infections, including meningitis, pneumonia, and sepsis. Conjugate Vaccines are typically administered to infants and young children, as their immune systems are not yet fully developed and are more susceptible to certain infections. In addition, these vaccines are often used in combination with other vaccines to provide broader protection against multiple diseases. Notable companies in the Conjugate Vaccine market include GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.